24/7 Market News Snapshot 08 January, 2025 – Silo Pharma, Inc. Common Stock (NASDAQ:SILO)

January 8, 2025

DENVER, Colo., 08 January, 2025 (247marketnews.com) – (Nasdaq:SILO) are discussed in this article.
Silo Pharma, Inc. (Nasdaq:SILO), a biopharmaceutical company focused on innovative therapies for stress-related psychiatric disorders, has recently experienced remarkable momentum in the market, with its shares trading at $1.834, marking a notable 68.26% increase from the previous close of $1.090. This surge, supported by a trading volume of over 9 million shares, reflects an upbeat investor sentiment towards Silo’s growth potential and therapeutic advancements.

The company’s positive trajectory comes amid the exciting news that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application 17/954,864, titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females.” This allowance is anticipated to culminate in an official patent issuance within the next 90 days, offering enhanced protection for Silo’s lead asset, SPC-15. Targeted at treating post-traumatic stress disorder (PTSD), SPC-15 exemplifies Silo’s commitment to addressing significant unmet medical needs in mental health.

Eric Weisblum, CEO of Silo Pharma, expressed enthusiasm about the forthcoming patent, stating that it broadens protection for SPC-15 and fortifies the company’s position within the biopharmaceutical landscape. The development of SPC-15 is further bolstered by an exclusive licensing agreement with Columbia University, enabling Silo to advance its research, manufacturing, and commercialization efforts globally.

SPC-15 is classified as a serotonin 5-HT4 receptor agonist and aims to utilize the FDA’s 505(b)(2) regulatory pathway, which could facilitate a more streamlined, efficient route to market. Additionally, ongoing preclinical studies with Columbia University underscore Silo’s dedication to delivering transformative solutions for those suffering from stress-induced disorders.

As Silo Pharma positions itself for future growth, it continues to lead with innovation in the biopharmaceutical sector, aiming to make a lasting impact in mental health treatment.

Related news for (SILO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.